羟苯磺酸钙治疗慢性肾脏病疗效的Meta分析  

A Meta-analysis of efficacy of calcium dobesilate in treatment of patients with chronic kidney disease

作　　者：张如玉[1] 肖爱国 孙东[1,2,3] 

机构地区：[1]徐州医学院内科学与诊断学教研室,江苏徐州221002 [2]伊犁哈萨克自治州奎屯医院 [3]徐州医学院附属医院

出　　处：《山东医药》2014年第31期4-6,共3页Shandong Medical Journal

基　　金：国家自然科学基金资助项目(81270769);江苏省医学重点人才项目(RC2011116);江苏省第七批"六大人才高峰"资助项目(2010-ws043);新疆伊犁哈萨克自治州奎屯市课题项目(201134)

摘　　要：目的系统评价羟苯磺酸钙治疗慢性肾脏病(CKD)的疗效及安全性。方法计算机全面检索Cochrane Database of Systematic Reviews、MEDLINE、EMbase、PubMed、知网等近十年来关于羟苯磺酸钙治疗CKD的随机对照试验(RCTs),根据文献纳入标准提取结局指标包括24 h尿蛋白定量(24 h UP)、血肌酐(SCr)、血尿素氮(BUN)、肌酐清除率(CCr)及尿酸(UA),用Review Manager 5.2软件进行Meta分析。结果共10个RCTs(包括973例患者)纳入研究,其中实验组(加用羟苯磺酸钙组)559例、对照组(常规治疗组或安慰剂组)414例。Meta分析显示,与对照组相比,实验组24 h UP降低(MD=-0.66,95%CI为-0.79to-0.52)、SCr降低(MD=-101.93,95%CI为-111.22to-92.64)、BUN降低(MD=-3.73,95%CI为-4.59to-2.88)、CCr升高(MD=4.28,95%CI为3.63to4.92)、UA降低(MD=-118.54,95%CI为-131.57to-105.50),P均<0.000 01。均未报道有严重不良反应发生。结论羟苯磺酸钙联合常规治疗可显著改善CKD患者的肾功能,安全性高。Objective To systematically assess the efficacy and safety of calcium dobesilate in treatment of patients with chronic kidney disease （CKD）.Methods Randomized controlled trials （RCTs） in databases such as Cochrane Database of Systematic Reviews, MEDLINE, EMbase, PubMed and Hownet regarding to calcium dobesilate in treatment of CKD patients were searched completely .According to the literature inclusion criteria , outcome indicators including 24 h urinary protein （24 h UP）, serum creatinine （SCr）, blood urea nitrogen （BUN）, creatinine clearance （CCr） and uric acid （UA） were extrac-ted.The qualified references underwent Meta-analysis with Review Manager 5.2.Results A total of 10 RCTs including 973 pooled patients were included , with 559 individuals in the experiment group and 414 individuals in the control group .Meta-analysis results showed：compared with the control group, 24 h UP decreased （MD=-0.66, 95%CI： -0.79 to -0.52, P〈0.000 01）, SCr decreased （MD=-101.93, 95%CI： -111.22 to -92.64, P〈0.000 01）, BUN decreased （MD=-3.73, 95%CI： -4.59 to -2.88, P〈0.000 01）, CCr increased （MD=4.28, 95%CI：3.63-4.92, P〈0.000 01）, and UA reduced （MD=-118.54, 95%CI： -131.57 to -105.50, P〈0.000 01） in the experiment group.Serious ad-verse reactions were not reported .Conclusion Calcium dobesilate combined with conventional therapy can improve renal function in patients with CKD significantly and has high safety .

关 键 词：羟苯磺酸钙 慢性肾疾病 META分析 

分 类 号：R692[医药卫生—泌尿科学]